PDF(Pubmed)
Abstract：
Clinician use of prescription drug monitoring programs (PDMPs) has been linked to better patient outcomes, but state requirements to use PDMPs are unevenly enforced. We assessed PDMP use in Minnesota, which requires opioid prescribers to hold accounts and, in most cases, search the PDMP before prescribing, but where enforcement authority is limited. Using 2023 PDMP data, we found that 4 in 10 opioid prescribers did not search and 2 in 10 did not hold an account. PDMP use was strongly associated with prescribing volume, but even among the top decile of opioid prescribers, 8% never searched the PDMP. Thirty-two percent of opioid fills came from clinicians who did not search the PDMP. Failures to use the PDMP may be driven by a lack of information about state requirements, beliefs that these requirements are not enforced, and the costs of accessing the PDMP relative to the benefits. These results highlight the potential for policy makers to promote safer and better-informed prescribing of opioids and other drugs by addressing the forces that have limited PDMP use so far.
摘要：
临床医生使用处方药监测计划（PDMPs）与更好的患者预后有关，但是州对使用PDMP的要求执行不均。我们评估了明尼苏达州的PDMP使用情况，这要求阿片类药物处方者持有账户，在大多数情况下,在处方前搜索PDMP，但在执法权有限的地方。使用2023PDMP数据，我们发现,十分之四的阿片类药物处方者没有进行搜索,十分之二的患者没有账户.PDMP使用与处方量密切相关，但即使在阿片类药物处方的前十位中，8%的人从未搜索过PDMP。32%的阿片类药物填充来自没有搜索PDMP的临床医生。无法使用PDMP可能是由于缺乏有关状态要求的信息，认为这些要求没有得到执行，以及与收益相关的访问PDMP的成本。这些结果凸显了决策者通过解决迄今为止限制PDMP使用的力量，促进更安全，更知情的阿片类药物和其他药物处方的潜力。
